| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6321cb52d6a2af2b80bd705d0bc9f9c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d11cb73f42b0fbdf22e771ed9a0664cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cee28849f025ddc070fcaba260ca6de0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_468acdcf7f6d54bd5a43cf981911bb5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ba6cf911f3e5b2927c69103d7380e37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51a0c49e5390c69aa92b87c3a892344c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
| filingDate |
2002-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adf7c8b18af5d239bb34aad6a4c2b182
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c879f908e35589313cf58fc524043e35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_759c96716e45164c3f237d8f02153ce3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc7f45b94ba130831e1204aff3c4a17b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d0d905a9dbe7ec4acd7c6396d1a8017 |
| publicationDate |
2004-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03054150-A3 |
| titleOfInvention |
Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| abstract |
Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes, and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes are provided. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin photosensitizer, such as riboflavin or a lumichrome-resistant photosenstizer, adding a non-toxic anti-oxidant, and exposing the lymphocytes to photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocytes cell preparation to the patients prior to transplantation are provided. |
| priorityDate |
2001-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |